IL2 and lymphoma: Pts with relapsed lymphoma (n = 29) or MBC (n = 28) were enrolled. In part I of the study, 34 pts were enrolled at 3 dose levels of ex vivo IL-2-activated NK cells. Lymphaphereses were performed on days 28 and 42 of s.c. IL-2 administration. ON ex vivo IL-2-activated apheresis product was reinfused the following day. In part II, 23 pts were enrolled at 3 dose levels of supplemental i.v. IL-2 bolus infusions, during s.c. IL-2 administration